Search Results

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS.

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.

Structure Therapeutics Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed underwritten public offering of 8,000,000 American depositary shares, each representing three ordinary shares.

Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures.

Structure Therapeutics Inc. (NASDAQ: GPCR) today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Structure Therapeutics Inc. announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares, each representing three ordinary shares, including the full exercise of the underwriters’ option to purchase up to 1,360,045 additional ADSs, at a public offering price of $52.50 per ADS.